5:29 PM · 23 April 2020

BREAKING : Strong declines on Wall Street - Gilead drug rejected in phase I testing

In the last minutes we have been observing a strong declines on Wall Street. This is linked to recent rumors that a Gilead drug called Remdesivir, which showed the most promising initial results in the treatment of  coronavirus, was rejected in phase I tests. S&P 500 retreats from around 2830 points, below 2790 points. Gilead's stock is currently losing 2%. This information was provided by the Financial Times.
S&P 500 dropped sharpy lower after information regarding coronavirus drug hit the markets. Source: xStation5
12 November 2026, 10:57 AM

🚨US100 on the verge of a breakout

12 November 2026, 7:39 AM

Morning Wrap: Nvidia sell-off weighs on indices - how many more Huang's affairs must the market price-in? (12.11.2026)

11 November 2026, 7:24 PM

📊Daily Summary: Tech sector drives Wall Street rebound, DAX leads in Europe

11 November 2026, 2:42 PM

US Open: Nasdaq 100 rises nearly 2% as CoreWeave and Nvidia rebound 📈 EURUSD hits its lowest level since May 12, 2026

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits